PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement: A case report.

Abstract Tumor necrosis factor (TNF-α) participates in the pathophysiology of Behcet's disease (BD) and myelodysplastic syndrome (MDS). Infliximab is recommaned for the most severe type of BD, however, there is little evidence for its effectiveness in BD associated MDS.
PMID
Related Publications

Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.

Good response to infliximab in a patient with deep vein thrombosis associated with Behçet disease.

Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.

Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390339
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Infliximab associated with life-threatening lung infection in a patient with
      Behcet disease with intestinal and hematopoietic system involvement: A case
      report.
PG  - e9202
LID - 10.1097/MD.0000000000009202 [doi]
AB  - RATIONALE: Tumor necrosis factor (TNF-alpha) participates in the pathophysiology 
      of Behcet's disease (BD) and myelodysplastic syndrome (MDS). Infliximab is
      recommaned for the most severe type of BD, however, there is little evidence for 
      its effectiveness in BD associated MDS. PATIENT CONCERNS: A 46-year-old female,
      initially diagnosed with intestinal BD and leukopenia was later diagnosed as MDS.
      Treatement with infliximab and other immunoregulators lead to life-threatening
      pneumonia. DIAGNOSIS: Intestinal BD associated with MDS involving trisomy 8.
      INTERVENTIONS: The patient initially treated with methylprednisolone,
      thalidomide, cyclosporine A, and infliximab, which lead to severe lung infection.
      Therefore, the patient was transferred to Intensive Care Unit for life
      supportive, anti-infection and immune improving therapy. OUTCOMES: The patient
      survived from the lung infection. With combination of methylprednisolone,
      thalidomide and cyclosporine A, the patient recovered from her intestinal
      ulceration and MDS manifestations. LESSONS: Infliximab treatment may not benefit 
      a patient with BD associated with MDS but place the patient at risk of infection.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Chen, Yong
AU  - Chen Y
AD  - Rheumatology and Immunology Department.
FAU - Shen, Yan
AU  - Shen Y
AD  - Rheumatology and Immunology Department.
FAU - Ma, Hai-Fen
AU  - Ma HF
AD  - Rheumatology and Immunology Department.
FAU - Cai, Jian-Fei
AU  - Cai JF
AD  - Rheumatology and Immunology Department.
FAU - Hua, Yan-Qin
AU  - Hua YQ
AD  - Medical Imagology Department, Huadong Hospital affiliated to Fudan University,
      Shanghai, P.R. China.
FAU - Zou, Jun
AU  - Zou J
AD  - Rheumatology and Immunology Department.
FAU - Guan, Jian-Long
AU  - Guan JL
AD  - Rheumatology and Immunology Department.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - B72HH48FLU (Infliximab)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - AIM
SB  - IM
MH  - Antirheumatic Agents/*adverse effects/*therapeutic use
MH  - Behcet Syndrome/*complications/*drug therapy
MH  - Cyclosporine/therapeutic use
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infliximab/*adverse effects/*therapeutic use
MH  - Methylprednisolone/therapeutic use
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*drug therapy/*etiology
MH  - Pneumonia/*chemically induced
MH  - Thalidomide/therapeutic use
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009202 [doi]
AID - 00005792-201712150-00089 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9202. doi: 10.1097/MD.0000000000009202.